Asthma-COPD overlap treatment market seen reaching $14.27 billion by 2030

The asthma-COPD overlap treatment market is projected to grow from $9.44 billion in 2025 to $14.27 billion by 2030, driven by smoking-related respiratory disease, precision medicine and aging populations. North America held the largest share in 2025, while Asia-Pacific is expected to grow fastest.

Why it matters: - The asthma-COPD overlap treatment market is expanding as more patients need care for overlapping respiratory symptoms that are harder to diagnose and treat with one-size-fits-all approaches. - Growth in biologics, digital monitoring and personalized therapies could shift how clinicians manage chronic lung disease over the next several years.

What happened: - The Business Research Company said the market will rise from $9.44 billion in 2025 to $10.23 billion in 2026, a CAGR of 8.4%. - The market is projected to reach $14.27 billion by 2030, with a forecast CAGR of 8.7%. - The report was released June 29, 2026, from London. - The company published a sample request here and the full report here.

The details: - Asthma-COPD overlap treatment typically combines inhaled corticosteroids, bronchodilators and lifestyle changes. - The treatment goal is to reduce airway inflammation, ease obstruction and slow disease progression. - The market’s near-term growth is tied to smoking-related respiratory illness, frequent misdiagnosis of overlap cases, limited personalization in respiratory care, more hospital admissions tied to exacerbations and continued dependence on traditional inhalation therapies. - The report identifies biologics, digital respiratory monitoring devices, personalized therapies, home-based chronic disease management and targeted anti-inflammatory treatments as future growth drivers. - North America held the largest market share in 2025. - Asia-Pacific is expected to be the fastest-growing region during the forecast period. - The report also covers South East Asia, Western Europe, Eastern Europe, South America and the Middle East and Africa.

Between the lines: - The market forecast reflects a wider move in respiratory care toward more precise patient matching, especially as biomarkers and molecular diagnostics improve phenotype classification. - The aging population adds demand because older adults are more vulnerable to chronic respiratory disease and related complications. - In February 2026, the Australian Institute of Health and Welfare reported that COPD accounted for 3.7% of Australia’s total disease burden in 2024 and caused 7,437 deaths in 2023. - In February 2024, the Personalized Medicine Coalition said the FDA approved 16 new personalized therapies for rare diseases in 2023, up from six in 2022. - In February 2025, the World Health Organization said the global population aged 60 and older is rising rapidly and is expected to surpass younger age groups in many regions by 2030.

What's next: - The report expects broader adoption of biologics and digital monitoring tools to support market expansion through 2030. - Care models that emphasize home-based management and targeted anti-inflammatory treatment are likely to gain more attention as respiratory systems move toward individualized care. - The Business Research Company said new 2026 report features include TAM analysis, company scoring matrix graphics, Excel-based forecasting dashboards, market hotspots infographics, and updated graphics and tables.

The bottom line: - The asthma-COPD overlap treatment market is moving from a niche respiratory segment toward a larger precision-medicine opportunity, with the biggest gains expected in Asia-Pacific and from therapies designed for specific patient phenotypes.